Every TDMx module pairs a patient record with a library of published, externally-validated population PK models for that drug.
Covers general wards through the ICU, with models tailored to obesity and haematopoietic stem-cell transplant recipients. Target: AUC24h/MIC 400–600, trough 10–20 mg/L.
From standard hospital dosing through renal replacement therapy and ECMO support. Target: %fT>MIC.
Supports intermittent, extended and continuous infusion strategies, including patients on renal replacement therapy. Target: %fT>MIC.
Spans adult, paediatric and neonatal (including extreme-preterm) populations, with extended-interval and traditional dosing strategies. Target: Cmax/MIC >10, AUC24h/MIC >70, trough <1–2 mg/L.
Paediatric and adult patients, with and without cystic fibrosis. Target: Cmax/MIC >10, AUC24h/MIC >70, trough <1–2 mg/L.
Critically-ill adult patients, including trauma and sepsis. Target: Cmax/MIC >10, AUC24h/MIC >70, trough <5–10 mg/L.
Prophylactic dosing for severe and moderate haemophilia A, spanning paediatric through adult patients. Target: trough ≥1 IU/dL (severe), ≥3–5 IU/dL (standard prophylaxis).
Maintenance dosing for inflammatory bowel disease (Crohn's disease and Ulcerative Colitis). Target: trough ≥5 mg/L (≥7–10 mg/L for refractory or perianal fistulising disease).
These are applications from the previous version of TDMx, kept online only so users with a project already in progress can complete it. They are no longer maintained or updated. From 1 October 2026 they will be taken offline — for anything new, please use the current TDMx applications above instead.
Model-Informed Precision Dosing